Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

E-GEOD-59294

ABSTRACT: Transcription profiling of skin from patients with moderate to severe atopic dermatitis before and after treatment with IL-4R inhibitor dupilumab (REGN668/SAR231893)

OTHER RELATED OMICS DATASETS IN: PRJNA254978

PROVIDER: E-GEOD-59294 | ExpressionAtlas | 2025-01-24

REPOSITORIES: ExpressionAtlas

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	E-GEOD-59294-analysis-methods.tsv	Tabular
	E-GEOD-59294-atlasExperimentSummary.Rdata	Rdata
	E-GEOD-59294-configuration.xml	Xml
	E-GEOD-59294-configuration.xml.beforeQC	Xml
	E-GEOD-59294-percentile-ranks.tsv	Tabular

Items per page:

1 - 5 of 92

Similar Datasets

E-GEOD-58558

Project description:Transcription profiling of skin samples from atopic dermatitis patients before and after treatment with cyclosporine A

2025-01-24 | E-GEOD-58558 | ExpressionAtlas

E-GEOD-27887

Project description:Transcription profiling by array of skin from patients with atopic dermatitis before and after treatment with narrow-band UVB radiation

2025-01-24 | E-GEOD-27887 | ExpressionAtlas

Transcription profiling of skin from patients with moderate to severe atopic dermatitis before and after treatment with IL-4R? inhibitor dupilumab (REGN668/SAR231893)

Project description:Atopic dermatitis (AD) is the most common inflammatory skin disease, with high unmet need for new therapies that are safe for chronic use. Emerging data suggest that TH2-cytokines play important roles in a variety of allergic and atopic conditions, including asthma and AD. In early phase clinical trials, dupilumab (a fully human monoclonal antibody against IL-4R? that potently blocks IL-4 and IL-13 signaling) rapidly and markedly improved clinical measures in adults with either asthma (with elevated eosinophil counts) or moderate-to-severe AD. The pathomechanisms that may be impacted by IL-4/13 blockade in these disease settings have not yet been characterized in detail. Transcriptome analyses in pre- and post-treatment skin biopsies from patients with moderate-to-severe AD treated with dupilumab or placebo in two completed clinical trials 18 Patients with AD treated with dupilumab or placebo. 28 biopsies in lesional (LS) Skin (16 pre-treatment and 12 post-treatment). 12 biopsies in non-lesional (NL) Skin (7 pre-treatment and 5 post treatment)

2014-12-04 | E-GEOD-59294 | biostudies-arrayexpress

E-GEOD-32924

Project description:Transcription profiling by array of lesional and non-lesional skin from atopic dermatitis patients and healthy individuals

2025-01-24 | E-GEOD-32924 | ExpressionAtlas

Blocking IL-4Rα with dupilumab (REGN668/SAR231893) rapidly suppresses major pathomechanisms in the skin of severe atopic dermatitis patients

Project description:Atopic dermatitis (AD) is the most common inflammatory skin disease, with high unmet need for new therapies that are safe for chronic use. Emerging data suggest that TH2-cytokines play important roles in a variety of allergic and atopic conditions, including asthma and AD. In early phase clinical trials, dupilumab (a fully human monoclonal antibody against IL-4Rα that potently blocks IL-4 and IL-13 signaling) rapidly and markedly improved clinical measures in adults with either asthma (with elevated eosinophil counts) or moderate-to-severe AD. The pathomechanisms that may be impacted by IL-4/13 blockade in these disease settings have not yet been characterized in detail. Transcriptome analyses in pre- and post-treatment skin biopsies from patients with moderate-to-severe AD treated with dupilumab or placebo in two completed clinical trials

2014-12-04 | GSE59294 | GEO

E-GEOD-30999

Project description:Expression data from skin biopsy samples from patients with moderate-to-severe psoriasis

2025-01-24 | E-GEOD-30999 | ExpressionAtlas

E-GEOD-36842

Project description:Transcription profiling by array of acute and chronic atopic dermatitis compared to normal skin

2025-01-24 | E-GEOD-36842 | ExpressionAtlas

Local and systemic changes in lipid profile as potential biomarkers for canine atopic dermatitis.

Project description:Lipids play a critical role in the skin as components of the epidermal barrier and as sig-naling molecules. Atopic dermatitis in dogs is associated with changes in the lipid composition of the skin, but whether these precede the onset of dermatitis or occur secondary to the dermatitis is unclear. We applied rapid lipid profiling mass spectrometry methods to skin and blood samples of dogs and determined changes following systemic treatment. Thirty control dogs and 30 atopic dogs with mild to moderate dermatitis were enrolled. Marked differences in lipid profiles were observed between control, nonlesional and lesional skin of dogs. Additionally, there were significant altera-tions in the lipid composition of the blood samples indicating systemic changes in lipid metabolism. Treatment with oclacitinib or lokivetmab resulted in a significant decrease of the disease clinical severity associated with changes in skin and blood lipids. A set of lipid features of the skin were selected as biomarkers that classified samples as control or atopic dermatitis with 95% accuracy, whereas blood lipids discriminated between control and atopic dogs with 82% accuracy. These data suggest that atopic dermatitis is a systemic disease and support the use of rapid lipid profiling to identify novel biomarkers.

2021-07-16 | MSV000087837 | MassIVE

E-GEOD-10433

Project description:Transcription profiling of human skin from patients with acne before and 1 week after isotretinoin (13-cis retinoic acid) treatment

2025-01-16 | E-GEOD-10433 | ExpressionAtlas

IL-4/IL-13 Inhibitors for Atopic Dermatitis Induce Psoriatic Rash Transcriptionally Close to Pustular Psoriasis

Project description:Dupilumab is an antibody targeting the IL-4/IL-13 receptors indicated for atopic dermatitis patients, but paradoxical psoriasis-like reactions have been reported under treatment. To understand the pathogenesis of DI-Pso, we performed a gene expression profiling study using microarray on skin biopsies of dupilumab-induced psoriasis, plaque psoriasis and AD compared with healthy control skin.

2023-01-16 | GSE185764 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data